Please login to the form below
Vertex
This page shows the latest Vertex news and features for those working in and with pharma, biotech and healthcare.
Pioneering research collaboration seeks cure for cystic fibrosis
Previously, it worked with Vertex Pharmaceuticals to develop the small molecule drugs that focus on ‘fixing’ the protein in the cells of CF patients, but now has its eye on a
Latest news
-
Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
Vertex has released results from its phase 1/2 trial for VX-880, a stem-cell-derived therapy that restores insulin production. ... However, Vertex aims to avoid this problem by encapsulating the pancreatic cells to shield them from immune attack.
-
Vertex expands further into cell and genetic therapies with a deal worth up to $1.2bn
Vertex will also make an investment in Arbor in the form of a convertible note. ... The deal with Arbor further enhances Vertex’s focus on cell and genetic therapies.
-
Vertex to lead development of CRISPR Therapeutics-partnered gene therapy
as we bring forward our broad gene and cell-based therapeutics portfolio,” said Jeffrey Leiden, executive chairman of Vertex. ... Along with Vertex/CRISPR Therapeutics, bluebird bio is also seeking to bring its gene therapy LentiGlobin for SCD (bb1111)
-
Vertex gains FDA fast track designation for diabetes stem cell therapy
Vertex gained VX-880 from its previous acquisition of Semma Therapeutics for $950m in September 2019. ... This will help to protect the islet cells from immune rejection, Vertex said in a statement.
-
ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more
Vertex/CRISPR Therapeutics make headway in sickle cell and beta thalassaemia. Also presenting data at ASH were Vertex and CRISPR Therapeutics, whose gene-editing therapy CTX001 scored some promising results in ... Reshma Kewalramani, chief executive
More from news
Approximately 62 fully matching, plus 84 partially matching documents found.
Latest Intelligence
-
Assessing the impact of rarity on French HTA and pricing decisions
Although its price is above the trend, it sits much lower than the likely price benchmark, Kalydeco (235, 000, also from Vertex).
-
Are smart deals a clever solution to UK market access?
Take Vertex for example, with its cystic fibrosis (CF) drug Kaftrio, which significantly improves lung function and overall quality of life for patients with CF. ... In 2020, the NHS agreed a ‘landmark deal’ with Vertex (see Figure 2), enabling
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
including Shire/Takeda, Actelion/J&J, Sanofi Genzyme, Alexion, Amicus, BioMarin, Sarepta and Vertex.
-
Health trust in a COVID-19 world – a unique opportunity for pharma
There were also some high-profile reimbursement stand-offs between pharma and the NHS (eg, Vertex/Orkambi).
-
The Cystic Fibrosis Buyers’ Club
Just Treatment is also urging the UK government to override Vertex’s patent via compulsory licensing or Crown Use Licence. ... Meticulous preparations. The supply of the generic drug comes from Argentinian pharma company Gador, whose Lucaftor is a copy
More from intelligence
Approximately 6 fully matching, plus 23 partially matching documents found.
Latest appointments
-
New hires at bluebird bio, BioNTech and Provention Bio
He has also held sales, marketing and medical affairs leadership roles at Sarepta Therapeutics, Vertex Pharmaceuticals and Gilead Sciences.
-
Red Consultancy appoints MD in its health division
Prior to joining Red, she was seconded to Vertex Pharmaceuticals as director of communication for the North region, where she was responsible for UK, Ireland and Nordics.
-
Hanover Brussels appoints Aurélie Marchand as account director
In her new role, Marchand will report to Eatwell and she will oversee the group’s portfolio of clients, which includes Sanofi Pasteur and Vertex Pharmaceuticals.
-
Rubius Therapeutics strengthens senior team
He has spent 16 years at Novartis holding roles in human resources, marketing, and sales, and he has also served Vertex Pharmaceuticals in various positions.
-
Vertex poaches new finance chief from Ironwood Pharmaceuticals
Boston-based biotech company appoints Tom Graney. Vertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer. ... Tom has the ideal blend of financial acumen, leadership skills,
More from appointments
Approximately 2 fully matching, plus 13 partially matching documents found.
Latest from PMHub
-
The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia
Several manufacturers are developing novel treatments for the disease, including Vertex, which has partnered with CRISPR Therapeutics to develop a gene-editing treatment for beta-thalassemia and sickle cell.
-
Warehousing of HCV patients reaches new high
New drugs from Vertex (Incivek) and Merck (Victrelis) have been welcomed because they are more effective, but they still need to be given with Interferon.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- NHS England announces rare genetic disorder fast-tracking service
- NICE sees ‘promise’ in four UTI tests that could help in fight against AMR
- Connectome competitiveness
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
PMHub
Redbow Consulting Group
Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
